SCHEMBL9892822

SCHEMBL9892822

O=C(Nc1nc(-c2ccccc2)ns1)[C@@H]1CCN1C1CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.56
ALOX15 P16050 1/20 0.56
MAPK1 P28482 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ADORA3 P0DMS8 9/20 0.56
CNR2 P34972 4/20 0.55
SMN1; SMN2 Q16637 5/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
LMNA P02545 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 1/20 0.47
POLB P06746 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9891546 0.82 CNR2 (0.47) TP53MAPK1HSD17B10CNR2SMN1; SMN2
SCHEMBL9892852 0.81 CNR2 (0.58) MAPK1HSD17B10CNR2SMN1; SMN2NPC1
SCHEMBL2573951 0.80 ADORA3 (0.54) TP53ALOX15MAPK1CASP1CASP7
SCHEMBL13257194 0.79 CNR2 (0.57) TP53ALOX15MAPK1CASP1CASP7
SCHEMBL9892847 0.77 CNR2 (0.65) TP53ALOX15MAPK1HSD17B10CNR2
SCHEMBL9892793 0.77 CNR2 (0.88) CNR2CNR1
SCHEMBL9892792 0.77 ALDH1A1 (0.62) HSD17B10CNR2CNR1
SCHEMBL9892827 0.77 CNR2 (0.48) ADORA3CNR2MEN1KMT2ACNR1
SCHEMBL9891992 0.76 ADORA3 (0.54) TP53ALOX15MAPK1CASP1CASP7
SCHEMBL13256841 0.74 SMN1; SMN2 (0.63) HSD17B10CNR2SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 TP53 4827/4885ALOX15 868/4885MAPK1 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.